Loading organizations...
Loading organizations...
Forward Therapeutics: biopharmaceutical company developing small molecule therapies for chronic inflammatory and immunological disorders.
Forward Therapeutics is a West Palm Beach, Florida-based biopharmaceutical company developing small molecule therapies for chronic inflammatory and immunological disorders. The preclinical and early clinical stage firm utilizes its Swift data-driven drug discovery engine to identify and optimize compounds targeting inflammation-driven diseases, specifically focusing on TNF signaling inhibitors designed to minimize immunosuppression. Operating with fewer than 25 employees, the enterprise generates under $5 million in revenue while currently advancing its lead investigational compounds, FT751 and FT2109, through early development phases and toward clinical trials. In November 2023, the organization secured $50 million in Series A financing backed by prominent institutional healthcare investors including BVF Partners LP, RA Capital Management, and OrbiMed. Established as the first biotech startup to partner with the Curie.Bio venture capital model, Forward Therapeutics was co-founded by Chief Scientific Officer Ewan Taylor.
Forward Therapeutics has raised $50.0M across 1 funding round.
Forward Therapeutics has raised $50.0M in total across 1 funding round.
Forward Therapeutics has raised $50.0M in total across 1 funding round.
Forward Therapeutics's investors include BVF Partners, OrbiMed, RA Capital Management.
Forward Therapeutics has raised $50.0M across 1 funding round. Most recently, it raised $50.0M Series A in November 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 8, 2023 | $50.0M Series A | BVF Partners | OrbiMed, RA Capital Management |